Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options (Q41158413)

27 September 2017

1 reference

title

Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options (English)

1 reference

27 September 2017

P Reusser

1

1 reference

27 September 2017

1 August 1996

1 reference

Journal of Hospital Infection

27 September 2017

1 reference

27 September 2017

33

1 reference

27 September 2017

4

1 reference

27 September 2017

235-248

1 reference

Comparative biology of latent varicella-zoster virus and herpes simplex virus infections

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Acyclovir: A Decade Later

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Herpes simplex virus resistant to acyclovir. A study in a tertiary care center

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS).

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Foscarnet Therapy in Five Patients with AIDS and Acyclovir-resistant Varicella-Zoster Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Occurrence and characterization of acyclovir‐resistant herpes simplex virus isolates: Report on a two—year sensitivity screening survey

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Prophylaxis: a strategy to minimise antiviral resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Foscarnet-resistant herpes simplex virus infection in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Meningoradiculoneuritis due to acyclovir-resistant varicella-zoster virus in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Foscarnet-resistant multidermatomal zoster in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Cytomegalovirus polyradiculopathy caused by a ganciclovir-resistant strain

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2896%2990010-9

7 January 2021

10.1016/S0195-6701(96)90010-9

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8864937